Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.
Department of Hematology, Juntendo University School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. komatsun@juntendo.ac.jp.
Norio
N
Komatsu
Department of Hematology and Oncology, University of Yamanashi, Yamanashi, 409-3898, Japan.
Keita
K
Kirito
Department of Gastroenterology and Hematology, University of Miyazaki, Miyazaki, 889-1692, Japan.
Kazuya
K
Shimoda
Department of Hematology, Kobe City Medical Center General Hospital, Kobe, 650-0047, Japan.
Takayuki
T
Ishikawa
Blood Transfusion Service, Mie University, Tsu, Mie, 514-8507, Japan.
Kohshi
K
Ohishi
Department of Hematology, Tokyo Medical University, Tokyo, 160-8402, Japan.
Kazuma
K
Ohyashiki
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, 010-8502, Japan.
Naoto
N
Takahashi
Novartis Pharma KK, Tokyo, 105-6333, Japan.
Hikaru
H
Okada
Novartis Pharma KK, Tokyo, 105-6333, Japan.
Taro
T
Amagasaki
Novartis Pharma KK, Tokyo, 105-6333, Japan.
Toshio
T
Yonezu
Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, 812-8582, Japan.
Koichi
K
Akashi